BACKGROUND
Alzheimer's disease is currently thought to contribute to about 75% of all cases of senile dementia that occur in the U.S. The disorder is marked by reduced levels of acetylcholine, development of amyloid plaques, and degeneration of brain tissue. It produces cognitive and coordinative dysfunctions with notable loss of memory. From the modern medical viewpoint, the cause of Alzheimer's disease is not yet established. There is a genetic component, since the frequency of the disease is higher in an identical twin or a child of a person with Alzheimer's disease, and the disease occurs with higher frequency in persons with the genetic disorder producing Down's Syndrome. But other factors, as yet unidentified, seem to be at least as important as genetics, based on the distribution of the disease. No infectious agent that might cause the disease has been identified, and there is no current evidence suggesting that an infection is involved.
Except for one of the rare genetic forms of the disease that causes early dementia, Alzheimer's usually does not occur in clinically obvious form before age 60. The incidence of the disorder increases with age, such that up to 30% of those over age 80 are believed to suffer from some degree of Alzheimer's disease. A recent study has suggested that early subtle signs-such as limited linguistic complexity-reveal the tendency to develop Alzheimer's disease. Such indicators may be detected before age 30. This would support the idea that the disorder has a genetic basis which yields an evident mental disease under the influence of the aging processes. It is possible, though not proven, that chemical pollutants, high fat diet, and sedentary life style may lead to the severe form of the disease.
Current orthodox medical treatment involves use of hydergine, dexedrine, and a variety of antidepressant drugs, all of which can produce modest improvements, especially in early stages of the disease. There are several experimental drugs in various stages of clinical trials that may improve the outcomes. Because of the advanced age of most sufferers, it is unlikely that even the most effective treatments would be able to produce complete remission.
In Europe, one of the main therapies for Alzheimer's disease is Ginkgo biloba leaf extract, which is a widely-used plant drug sold in pharmacies. This flavonoid-rich extract promotes blood circulation to the brain as well as to other parts of the body. Because a large investment in research dollars has been made in testing ginkgo extract, many people do not realize that the same or similar effects may be attained by using other herbs that are a source of circulation-promoting flavonoids.
by Subhuti Dharmananda, Ph.D., Director, Institute for Traditional Medicine, Portland, Oregon
http://www.itmonline.org/arts/alzheimers.htm
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment